Is HBOC vasoconstriction only a side effect or an architecture-and-control mechanism?
Moving hemoglobin from an intact red blood cell into plasma changes more than location. It changes molecular scale, compartmentalization, diffusion barriers, nitric-oxide kinetics and vascular exposure. This research concept asks whether the design target should be understood as controlled vascular interaction in support of tissue oxygen delivery, rather than as oxygen carriage considered in isolation.
Hemoglobin is the core. Regulation is layered around it.
Globin-heme chemistry provides a highly successful molecular solution for reversible oxygen binding. Vertebrate physiology places that molecular function inside progressively broader layers of control: the red cell, circulation, microcirculation, tissue diffusion, cellular oxygen sensing and metabolism.
This is not a claim that evolution followed a simple linear ladder. Different species solve oxygen-delivery problems at different levels. The relevant observation is that the same fundamental oxygen-binding chemistry operates within very different biological architectures.
A cell-free carrier occupies a different physical world from an RBC.
A published HBOC-201 reference reports an approximate molecular diameter of 8 nm, compared with approximately 7,000 nm for a human red blood cell. That is about an 875-fold difference in linear dimension.
BHOC communication has used the deliberately conservative phrase “more than 400× smaller than an RBC” to describe this architectural contrast within the polymerized-hemoglobin design space. Final hydrodynamic size and size distribution remain product-specific analytical attributes and must be measured for the defined formulation.
Smaller size may create access — and removes natural spatial protection.
A molecular-scale oxygen carrier can distribute in plasma and access spaces unavailable to an intact red cell. But the same change also removes much of the spatial and diffusional separation between hemoglobin and the vascular endothelium. Size is therefore not simply an advantage or disadvantage. It is a design variable linked to oxygen transport, extravasation, nitric-oxide exposure, rheology and microvascular behavior.
A 2026 study directly reinforces this design logic: molecular size was shown to govern NO scavenging and vascular reactivity, with an intermediate polymer size producing the best balance among endothelial function, NO bioavailability and hemodynamic behavior in the tested models.
The same hemoglobin chemistry behaves differently inside an RBC and free in plasma.
Cell-free hemoglobin reacts extremely rapidly with nitric oxide (NO). Experimental work by Vaughn and colleagues reported that intact RBCs consume NO approximately 500–1,000 times more slowly than free hemoglobin. Subsequent work likewise described the RBC reaction with NO as roughly three orders of magnitude slower than the reaction with cell-free Hb.
This difference cannot be reduced to one membrane effect. Extracellular diffusion, the red-cell-free layer adjacent to the vessel wall, membrane permeability and intracellular diffusion all contribute to the effective separation between endothelial NO and the high hemoglobin concentration inside the RBC.
That makes compartmentalization a form of physiological control. Nature can carry a very large mass of highly reactive hemoglobin through the circulation while limiting the rate at which that hemoglobin directly consumes endothelial NO.
Two proposed scales of vascular regulation.
In an earlier BHOC LinkedIn concept, Archil Jaliashvili proposed a deliberately simplified contrast between local RBC regulation and a broader vascular response to cell-free BHOC. It was presented as a hypothesis for discussion, not as a universal physiological law.
Reframe the problem from a label to a controllable architecture.
What has historically been classified simply as an HBOC “vasoconstrictive side effect” may also need to be examined as part of an architecture-and-control mechanism created when hemoglobin is moved from the spatially regulated RBC environment into plasma.
This does not mean vasoconstriction should be assumed beneficial, and it does not mean NO scavenging should be maximized. The hypothesis is narrower: vascular behavior should be treated as an engineered, measurable part of oxygen-delivery performance rather than as a binary property detached from dose, molecular size, oxygen unloading and tissue perfusion.
The engineering objective may therefore be to identify the appropriate magnitude, location and kinetics of vascular interaction in a defined physiological context so that oxygen carriage, perfusion pressure, microvascular flow and tissue oxygenation remain compatible.
NO scavenging is an important mechanism of HBOC-associated vasoconstriction, but it is not the only proposed mechanism. Oxygen autoregulation, solution viscosity and shear-dependent endothelial signaling, extravasation and other pathways can contribute. A valid BHOC hypothesis must therefore be tested as a multi-variable system rather than reduced to one reaction.
A hypothesis becomes useful only when it can fail.
Nature did not solve oxygen delivery with only one architecture.
Related perspective: Franck Zal
Franck Zal has repeatedly argued for an evolution-first, biomimetic approach to oxygen-carrier biotechnology: nature has tested biological solutions under extreme conditions for billions of years, and engineering can begin by understanding those solutions rather than assuming that a new design starts from zero.
His work with the naturally extracellular hemoglobin of Arenicola marina is especially relevant as a comparative example: extracellular hemoglobin can exist within a very different evolved molecular architecture from mammalian RBC-contained hemoglobin.
Boundary: this comparison is a scientific perspective, not evidence that a mammalian polymerized cell-free hemoglobin will reproduce the biology, safety or vascular behavior of marine extracellular hemoglobin. It is also not an endorsement of BHOC by Franck Zal.
Related author perspective: Archil Jaliashvili
An earlier Archil Jaliashvili post expressed the central architectural idea in simplified form: evolution conserved hemoglobin as the oxygen-binding core and built the red-cell system around it. The present hypothesis develops that thought more rigorously by separating molecular chemistry from the cellular and vascular architecture in which it operates.
Concept first. Validation next.
This page is an author-generated research concept. It distinguishes established observations — RBC compartmentalization, rapid cell-free Hb/NO chemistry, formulation-dependent HBOC vasoactivity and molecular-size effects — from the proposed BHOC interpretation that these variables can be treated as a controllable oxygen-delivery architecture.
The next scientific step is not to declare the hypothesis correct. It is to define measurable product attributes and physiological endpoints that can determine where the hypothesis holds, where it fails and whether any observed vascular response improves or impairs net tissue oxygen delivery.